Published :
Tables : 19
Figures : 31
Category : Healthcare
No. of Pages : 200
Report Code : HC-1015
Biosimulation Market Introduction: Biosimulation Market is predicted to value over USD 4.3 billion by 2027 end with a CAGR of over 15.5% during the forecast period 2020 to 2027. Bio-simulation is a distinct part of systems biology, which gives information about complex biological systems in disease and health. The bio-simulation is also referred to as in-silico biology, which means biological experiments have to carry out in the computer. It is an entirely new concept in the drug development industry, which relies on expressing the biological systems with mathematical expressions, thus, capturing biological elements and their relationships, and simulating the behaviour of certain systems in different situations. There are different types of bio-simulation approaches are available which gives outcome based on the complexity of biosystem and the disease- drug target. It credits the reduction and replacement of animal and human experimentations as well as improves the knowledge of how patients need to administer medicine. Biosimulation has a huge demand for drug development for mimicking disease indication. It is used to simulate the disease indication and decrease the effort of research. Increasing attrition rates of drug development have increased the dependence of research companies on simulation techniques for minimizing capital investments. Additionally, the rapid advancement of technologies has integrated the biosimulation process in clinical trials and offers complete automation. Biosimulation techniques also minimize human errors and increase the efficiency of the development process. Further, it also decreases the development time and speeds up the whole drug discovery process. All these factors led to robust growth of the market during the forecast period. Global Biosimulation market is expected to witness a high adoption rate due to increasing awareness of simulation techniques among the drug developing companies. North America market is expected to account major share in the global market due to high R&D investments of top drug manufacturers. It was followed by the European region and it also accounts significant share over the forecast period. It is expected to witness high growth rate over the forecast period. Both North America and Europe market is expected to remain dominant in the global market over the forecast period. The Asia Pacific, Latin America and Rest of the world market are expected to account a small fraction of market share due to less adoption. Biosimulation market players include: Certara, Simulations Plus, Dassault Systèmes, Schrödinger, ACD/Labs, Chemical Computing Group, Physiomics, Evidera, In silico biosciences, INOSIM Software, Insilico Biotechnology, LeadInvent Technologies, Rosa, Nuventra Pharma , and Genedata. Biosimulation Market Segmentation: By Product & Service • Software o Molecular Modeling and Simulation Software o PBPK Modeling and Simulation Software o PK/PD Modeling and Simulation Software o Trial Design Software o Toxicity Prediction Software o Other Biosimulation Software • Services o In-house Services o Contract Services By Application Drug Development Drug Discovery Other Applications By Delivery Model Subscription Models Ownership Models By End User Pharmaceutical and Biotechnology Companies Research Institutes Contract Research Organizations Regulatory Authorities Other End Users By Region Europe North America APAC Latin America Rest of World Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global market by product & service, by application, by delivery model, by end user and by region. To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Biosimulation Market is predicted to value over USD 4.3 billion by 2027 end with a CAGR of over 15.5% during the forecast period 2020 to 2027.
Bio-simulation is a distinct part of systems biology, which gives information about complex biological systems in disease and health. The bio-simulation is also referred to as in-silico biology, which means biological experiments have to carry out in the computer. It is an entirely new concept in the drug development industry, which relies on expressing the biological systems with mathematical expressions, thus, capturing biological elements and their relationships, and simulating the behaviour of certain systems in different situations. There are different types of bio-simulation approaches are available which gives outcome based on the complexity of biosystem and the disease- drug target. It credits the reduction and replacement of animal and human experimentations as well as improves the knowledge of how patients need to administer medicine.
Biosimulation has a huge demand for drug development for mimicking disease indication. It is used to simulate the disease indication and decrease the effort of research. Increasing attrition rates of drug development have increased the dependence of research companies on simulation techniques for minimizing capital investments. Additionally, the rapid advancement of technologies has integrated the biosimulation process in clinical trials and offers complete automation. Biosimulation techniques also minimize human errors and increase the efficiency of the development process. Further, it also decreases the development time and speeds up the whole drug discovery process. All these factors led to robust growth of the market during the forecast period. Global Biosimulation market is expected to witness a high adoption rate due to increasing awareness of simulation techniques among the drug developing companies.
North America market is expected to account major share in the global market due to high R&D investments of top drug manufacturers. It was followed by the European region and it also accounts significant share over the forecast period. It is expected to witness high growth rate over the forecast period. Both North America and Europe market is expected to remain dominant in the global market over the forecast period. The Asia Pacific, Latin America and Rest of the world market are expected to account a small fraction of market share due to less adoption.
Biosimulation market players include:
Certara, Simulations Plus, Dassault Systèmes, Schrödinger, ACD/Labs, Chemical Computing Group, Physiomics, Evidera, In silico biosciences, INOSIM Software, Insilico Biotechnology, LeadInvent Technologies, Rosa, Nuventra Pharma , and Genedata. Biosimulation Market Segmentation:
By Product & Service
• Software o Molecular Modeling and Simulation Software o PBPK Modeling and Simulation Software o PK/PD Modeling and Simulation Software o Trial Design Software o Toxicity Prediction Software o Other Biosimulation Software • Services o In-house Services o Contract Services
By Application
By Delivery Model
By End User
By Region
Competitive Landscape:
FutureWise Takeaways:
Objectives of the Study:
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data From Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data From Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Biosimulation Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards And Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Biosimulation Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Biosimulation Market, By Product & Services Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Software 7.1.1. Molecular Modeling and Simulation Software 7.1.2. PBPK Modeling and Simulation Software 7.1.3. PK/PD Modeling and Simulation Software 7.1.4. Trial Design Software 7.1.5. Toxicity Prediction Software 7.1.6. Other Biosimulation Software 7.2. Services 7.2.1. In-house Services 7.2.2. Contract Services 8. Global Biosimulation Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Drug Development 8.2. Drug Discovery 8.3. Other Applications 9. Global Biosimulation Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Biopharmaceutical Companies 9.2. Contract Research Organization 9.3. Academic Institutes 10. North America Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2020-2027 11. Europe Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Switzerland 11.2.9. Rest of Western Europe 12. Asia Pacific Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) - along with expected regulatory needs 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Japan 12.2.2. China 12.2.3. Singapore 12.2.4. India 12.2.5. Australia and New Zealand 12.2.6. ASEAN 12.2.7. South Korea 12.2.8. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 13. Latin America Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Regional Market Trends 13.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.3.1. Brazil 13.3.2. Venezuela 13.3.3. Argentina 13.3.4. Rest of Latin America 13.4. Market Size (USD Million) Forecast for Latin America 2020-2027 14. Rest of World Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Saudi Arabia 14.2.2. UAE 14.2.3. South Africa 14.2.4. Egypt 14.3. Market Size (USD Million) Forecast for MEA 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 15.1. Schrödinger 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Simulation Plus 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. INOSIM Software Dassault Systèmes 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. LeadInvent Technologies 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5. Schrödinger 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.6. Simulation Plus 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.7 INOSIM Software Dassault Systèmes 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.8. LeadInvent Technologies 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.9. Schrödinger 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.10. Simulation Plus 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.11. INOSIM Software Dassault Systèmes 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.12. LeadInvent Technologies 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.13. Schrödinger 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.14. Simulation Plus 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.15. INOSIM Software Dassault Systèmes 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 16. FutureWise SME key takeaway points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data From Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data From Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Biosimulation Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards And Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Biosimulation Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Biosimulation Market, By Product & Services Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1. Software 7.1.1. Molecular Modeling and Simulation Software 7.1.2. PBPK Modeling and Simulation Software 7.1.3. PK/PD Modeling and Simulation Software 7.1.4. Trial Design Software 7.1.5. Toxicity Prediction Software 7.1.6. Other Biosimulation Software 7.2. Services 7.2.1. In-house Services 7.2.2. Contract Services 8. Global Biosimulation Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Drug Development 8.2. Drug Discovery 8.3. Other Applications 9. Global Biosimulation Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Biopharmaceutical Companies 9.2. Contract Research Organization 9.3. Academic Institutes 10. North America Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) along with expected regulatory needs 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2020-2027 11. Europe Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5. Spain 11.2.6. Russia 11.2.7. Poland 11.2.8. Switzerland 11.2.9. Rest of Western Europe 12. Asia Pacific Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) - along with expected regulatory needs 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Japan 12.2.2. China 12.2.3. Singapore 12.2.4. India 12.2.5. Australia and New Zealand 12.2.6. ASEAN 12.2.7. South Korea 12.2.8. Rest of Asia Pacific 12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 13. Latin America Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Regional Market Trends 13.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.3.1. Brazil 13.3.2. Venezuela 13.3.3. Argentina 13.3.4. Rest of Latin America 13.4. Market Size (USD Million) Forecast for Latin America 2020-2027 14. Rest of World Biosimulation Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Saudi Arabia 14.2.2. UAE 14.2.3. South Africa 14.2.4. Egypt 14.3. Market Size (USD Million) Forecast for MEA 2020-2027 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 15.1. Schrödinger 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Simulation Plus 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. INOSIM Software Dassault Systèmes 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. LeadInvent Technologies 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview
15.5. Schrödinger 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.6. Simulation Plus 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.7 INOSIM Software Dassault Systèmes 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.8. LeadInvent Technologies 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.9. Schrödinger 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.10. Simulation Plus 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.11. INOSIM Software Dassault Systèmes 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.12. LeadInvent Technologies 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.13. Schrödinger 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.14. Simulation Plus 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.15. INOSIM Software Dassault Systèmes 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 16. FutureWise SME key takeaway points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics